Q3 Revenue Up 26% to $9.8M, But Guidance Range Trimmed at Top End
FOCL has more than doubled off its 52-week low of $1.82 on light trading volume (0.4× avg).
Summary
FocalTherics posted Q3 2026 revenue of $9.8M, up 26% year-over-year, with U.S. procedure volume up 32% and gross margin expanding to 51.4% from 46.6%. Net loss narrowed to $4.5M, or $0.10 per share, versus $5.9M, or $0.16, a year ago, helped by a $2.6M non-cash warrant fair-value gain. The company sold seven Focal One systems in the quarter versus six a year earlier and grew its installed base to 192 systems, 98 of them in the U.S. The offset: full-year 2026 revenue guidance was narrowed to $50.0-$52.0M from $50.0-$54.0M, cutting the top end by $2M even as the low end held. Cash stood at $56.3M at quarter-end, following the $40M ADS offering completed in August. The quarter shows steady commercial traction but the trimmed ceiling suggests the second-half ramp is tracking toward the lower half of prior expectations.
At the time of this announcement, FOCL was trading at $4.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162.7M. The 52-week trading range was $1.82 to $6.40. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.